$49.1M
The grant from the US Advanced Research Projects Agency for Health will support the POSEIDON programme for early oncology intervention.
Owlstone Medical
Owlstone Medical creates breath biopsy technology for non-invasive disease detection.
$115MTotal raised
Owlstone Medical develops non-invasive diagnostic tools that analyse volatile organic compounds in breath samples to detect diseases early.
Categories
Founders
Billy Boyle
Co-founder and CEO
Billy serves as co-founder and chief executive officer of Owlstone Medical, having previously co-founded Owlstone. He also brings academic research experience from the University of Cambridge.
LinkedInDR
David Ruiz-Alonso
Co-founder
Investors
- $49.1M
- £1.7M
- £22.0M
- £42.0M
Funding history
£1.7M
The funding will support proof-of-principle work for detecting Pseudomonas aeruginosa infections in patients.
£22.0M
Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.
£42.0M
The oversubscribed financing round will support the commercialisation of proprietary breath biopsy tests.